American Diabetes Association
1701 North Beauregard Street
Alexandria
Virginia
22311
United States
Tel: 800-342-2383
Website: http://www.diabetes.org/
Email: customerservice@diabetes.org
592 articles with American Diabetes Association
-
American Diabetes Association® Launches New Communications & Engagement Platform to Empower Advocates
9/25/2019
New Platform will Empower the 30 Million Americans with Diabetes to Advocate for Legislation that Promotes Insulin and Drug Affordability
-
The American Diabetes Association® Applauds the Insulin Price Reduction Act, Introduced Today by the Senate Diabetes Caucus
7/22/2019
The American Diabetes Association strongly supports the introduction of the Insulin Price Reduction Act in the United States Senate.
-
Clinical Catch-up for June 10-14
6/17/2019
Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look. -
Almost 15,000 physicians, scientists, health care professionals and industry representatives from around the globe presented research, treatment recommendations and advances toward a diabetes cure at the American Diabetes Association's 79th Scientific Sessions in San Francisco this week.
-
Safety of Linagliptin for Adults with Type 2 Diabetes Who Have High Risk of Cardiovascular and/or Renal Disease Examined in CARMELINA
6/11/2019
International trial of nearly 7,000 people indicates a noninferior risk, presented at the ADA's Scientific Sessions
-
Linagliptin and Glimepiride Have Comparable Cardiovascular Safety Effects in Type 2 Diabetes at High Cardiovascular Risk
6/11/2019
Results of CAROLINA trial, a multi-center, international clinical trial of more than 6,000 adults and the longest-running study dedicated to cardiovascular outcomes in people with type 2 diabetes, presented at ADA's Scientific Sessions
-
Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta®
6/11/2019
CAROLINA® demonstrated no increased cardiovascular risk for Tradjenta® (linagliptin) versus glimepiride in the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor
-
DarioHealth Reports Improvement in Glycemic Outcomes With Key Diabetes Findings at the American Diabetes Association's 79th Scientific Sessions
6/11/2019
Digital Therapeutics leader DarioHealth caps off successful week at the ADA with Two Studies Presenting New Real-World Data in the Field of Diabetes
-
“Over the past few years there has been a good amount of information presented at ADA. This year though, with all of the data presented, this was the most exciting year,” Todd Hobbs, U.S. chief medical officer of Novo Nordisk, told BioSpace in an exclusive interview.
-
Type 1 Diabetes May Affect Brain Development, Beginning in Early Childhood
6/10/2019
DirecNet study indicates youth with early-onset T1D have mild but detectable differences in brain development, based on research presented at the ADA's Scientific Sessions
-
Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes
6/10/2019
REWIND data showed a consistent effect in people with and without established cardiovascular disease
-
Sihuan's Abstracts regarding Clinical Trial Progress of SGLT-2 Inhibitor Selected for Poster Presentation at the American Diabetes Association's Scientific Sessions
6/10/2019
Sihuan Pharmaceutical Holdings Group Ltd., the largest cardio-cerebral vascular drug manufacturer in China's prescription drug market, announced that three abstracts regarding the clinical trial of the Group's patented innovative drug Janagliflozin have been selected for poster presentation at the American Diabetes Association's 79th Scientific Sessions.
-
Insulet’s Omnipod® Horizon™ Hybrid Closed-Loop System Improves Glycemic Control in Patients as Young as Two Years Old with Type 1 Diabetes
6/10/2019
Pediatric Scientific Data for the Omnipod Horizon System Presented at the American Diabetes Association’s 79th Scientific Sessions
-
Dulaglutide Reduces Cardiovascular Disease in People with Type 2 Diabetes
6/10/2019
Presented at ADA's Scientific Sessions, REWIND trial confirms dulaglutide reduces CVD risk regardless of CV history
-
Real-World Data from Guardian(TM) Connect and Sugar.IQ(TM) Reveal Improved Diabetes Outcomes
6/10/2019
Sugar.IQ Insights Viewed as Helpful and Enable Users to Avoid Diabetes-Related Events up to Four Hours in Advance
-
Whole Biome Presents Positive Clinical Data at American Diabetes Association's 79th Scientific Sessions
6/10/2019
Findings Demonstrate Clinical Efficacy of Microbiome Medical Food Product and Validate Unique Mechanism of Action
-
PolarityTE Announces Final Clinical Data from Pilot Study Showing Closure of Diabetic Foot Ulcers Using SkinTE
6/10/2019
PolarityTE, Inc., a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced the final results from a pilot study on the use of its SkinTE™ product for hard-to-treat diabetic foot ulcers.
-
Dapagliflozin Reduces Progression of Kidney Disease and Renal Death in People with Type 2 Diabetes
6/10/2019
Sub-analysis of data from DECLARE-TIMI 58 trial shows a 47% reduction of composite kidney function decline, end-stage renal disease or death, presented today at the ADA's Scientific Sessions
-
A Phase III trial compared Sanofi’s Soliqua/Suliqua to other GLP-1 receptor agonists (GLP-1 RA), with Soliqua showing a superior decrease of average blood sugar level (HbA1c) after 26 weeks.
-
Two RISE Clinical Trials in Youth and Adults with Impaired Glucose Tolerance or Newly Diagnosed Type 2 Diabetes Reveal Surprising Differences in Beta-Cell (β-cell) Function During and After Treatment
6/9/2019
RISE researchers present Adult Medication Study results at the ADA's Scientific Sessions and share the first direct comparison for youth and adult studies